Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

64.41
-0.2200-0.34%
Pre-market: 63.89-0.5168-0.80%04:22 EDT
Volume:1.95M
Turnover:125.96M
Market Cap:12.45B
PE:169.95
High:65.33
Open:63.83
Low:63.64
Close:64.63
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:1.02
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:1.97
PE(LYR):35.78

Loading ...

BioMarin reports new data from Phase 3 CANOPY-HCH-3 study

TIPRANKS
·
Yesterday

BioMarin Submits FDA sNDA to Expand Voxzogo Use to Children with Hypochondroplasia

Reuters
·
Yesterday

Biomarin Announces Positive Results of Phase 3 Voxzogo® (Vosoritide) Study in Hypochondroplasia Published in Nejm Evidence

THOMSON REUTERS
·
Yesterday

Clearway Energy Names Steven Ryder CFO Effective Oct. 1

Reuters
·
Yesterday

BioMarin Chief Legal Officer George Eric Davis Disposes of 17,557 Shares Worth $1.16 Million

Reuters
·
Sep 04

BioMarin Management Presents at Wells Fargo Healthcare Investor Conference

Reuters
·
Sep 02

CASI Pharmaceuticals Sells Alesta Stake to BioMarin for Us$5.9 Million

Reuters
·
Sep 02

How BioMarin’s Navepegritide Settlement and Royalty Deal with Ascendis Could Shape BioMarin (BMRN) Investors

Simply Wall St.
·
Sep 02

Barfresh Food Names CEO Delle Coste Interim CFO as Lisa Roger Retires

Reuters
·
Sep 02

BioMarin Pharmaceutical is Maintained at Overweight by Piper Sandler

Dow Jones
·
Sep 02

Biomarin Announces Close of the Alesta Therapeutics Acquisition

THOMSON REUTERS
·
Sep 01

Press Release: BioMarin Announces Close of the Alesta Therapeutics Acquisition

Dow Jones
·
Sep 01

BioMarin price target raised to $90 from $88 at Piper Sandler

TIPRANKS
·
Sep 01

BioMarin Pharmaceutical (BMRN) Receives a Buy from Wells Fargo

TIPRANKS
·
Sep 01

Biomarin Pharmaceutical Inc. : H.c. Wainwright Raises Target Price to $60 from $59

THOMSON REUTERS
·
Aug 31

U.s. Stocks on the Move-Pinterest, Intel, Slb

Reuters
·
Aug 31

Movement Alert|Biomarin Pharmaceutical Rises 5.08% in Pre-Market Trading, Reaches Global Patent Settlement With Ascendis Pharma Securing Up to 20% Royalty on Yuviwel Sales

Market Focus
·
Aug 31

Ascendis Enters Global Settlement, License Deal with BioMarin for Yuviwel Royalties

Reuters
·
Aug 31

Intel, ServiceNow, Chevron, Strategy, and More Stocks That Explain Today's Market

Dow Jones
·
Aug 31

BioMarin to receive 20% royalty on net sales of Yuviwel from Ascendis Pharma

TIPRANKS
·
Aug 31